BIIB
Biogen Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+46/100
Last price
222.50
▼ 1.09 (0.49%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
222.65
Prev close
223.59
Day high
225.97
Day low
218.00
Volume
1.01M
Market cap
$32.93B
P/E (TTM)
39.59
52W range
138.00 – 230.49
Day trading desk
Gap from prior close
-0.42%
Prior close 223.59
VWAP
222.68
-0.08% from price
Relative volume
1.61×
Unusually busy
Session range
3.66%
218.00 – 225.97
Position in range
56%
Mid range
ATR (14D)
5.54
2.49% of price
Prior day high
223.85
PDH
Prior day low
218.22
PDL
Bid / ask spread
—
Quote not published
Session volume
1.74M
Avg 1.08M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.84%
-3.8%
1M
+0.93%
-0.2%
3M
+11.24%
+6.7%
6M
+26.92%
+8.7%
YTD
+26.65%
+12.4%
1Y
+39.41%
+23.0%
3Y
-13.28%
-95.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BIIB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+16.20K
Net buying
Buy transactions
12
17.38K shares
Sell transactions
1
1.19K shares
Net transactions
+13
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
277.78K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 2, 26 | GODBOUT SEAN Officer |
— | 27 | — | Direct |
| Aug 4, 26 | MINOR LLOYD B. Director |
SELL | 1.19K | $239.75K | Direct |
| Jun 9, 26 | PANGALOS MENELAS N Director |
— | 2.37K | — | Direct |
| Jun 9, 26 | FREIRE MARIA C Director |
STOCK | 2.00K | $0 | Direct |
| Jun 9, 26 | ROWINSKY ERIC K. Director |
STOCK | 1.50K | $0 | Direct |
| Jun 9, 26 | PATOLAWALA MONISH D Director |
STOCK | 1.50K | $0 | Direct |
| Jun 9, 26 | LANGER SUSAN Director |
STOCK | 1.50K | $0 | Direct |
| Jun 9, 26 | PANGALOS MENELAS N Director |
STOCK | 1.50K | $0 | Direct |
| Jun 9, 26 | MINOR LLOYD B. Director |
STOCK | 1.50K | $0 | Direct |
| Jun 9, 26 | MANTAS JESUS B Director |
STOCK | 1.50K | $0 | Direct |
| Jun 9, 26 | SHERWIN STEPHEN A Director |
STOCK | 1.50K | $0 | Direct |
| Jun 9, 26 | HAWKINS WILLIAM A III Director |
STOCK | 1.50K | $0 | Direct |
| May 1, 26 | KEENEY ADAM JAMES Officer |
— | 939 | — | Direct |
| Apr 1, 26 | GODBOUT SEAN Officer |
— | 181 | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALEXANDER SUSAN H |
Officer | 61.89K | Conversion of Exercise of derivative security |
DORSA CAROLINE D |
Director | 31.00K | Stock Award(Grant) |
GREGORY GINGER |
Officer | 22.36K | Conversion of Exercise of derivative security |
KRAMER ROBIN C. |
Chief Financial Officer | 11.47K | Conversion of Exercise of derivative security |
MANTAS JESUS B |
Director | 11.26K | Stock Award(Grant) |
MCDONNELL MICHAEL R |
Chief Financial Officer | 24.34K | Conversion of Exercise of derivative security |
MURPHY NICOLE |
Officer | 19.61K | Purchase |
ROWINSKY ERIC K. |
Director | 25.84K | Stock Award(Grant) |
SHERWIN STEPHEN A |
Director | 15.19K | Stock Award(Grant) |
VIEHBACHER CHRISTOPHER |
Chief Executive Officer | 29.92K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$32.93B
Enterprise value$40.00B
Revenue (TTM)$10.03B
Gross profit$7.85B
EBITDA$3.36B
Net income$834.60M
EPS (TTM)$5.63
Free cash flow$1.27B
Total cash$1.28B
Total debt$8.36B
Book value / share$127.61
Shares outstanding147.75M
Float147.22M
Short % of float4.39%
Dividend yield0.00%
Beta (5Y)0.09
Valuation & profitability ratios
Trailing P/E39.59
Forward P/E13.48
PEG ratio2.30
Price / sales—
Price / book1.75
EV / revenue3.99
EV / EBITDA11.91
Gross margin78.32%
Operating margin25.06%
Profit margin8.32%
Return on equity4.58%
Return on assets5.21%
Debt / equity44.33
Current ratio1.87
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $9.89B | $9.68B | $9.84B | $10.17B | +2.2% |
| Operating revenue | $9.89B | $9.68B | $9.84B | $9.69B | +2.2% |
| Cost of revenue | $2.40B | $2.31B | $2.53B | $2.28B | +4.1% |
| Gross profit | $7.49B | $7.37B | $7.30B | $7.90B | +1.6% |
| Research & development | $1.78B | $1.98B | $2.45B | $2.23B | -10.2% |
| Selling, general & admin | $2.43B | $2.40B | $2.55B | $2.40B | +1.2% |
| Total operating expense | $5.02B | $5.09B | $5.45B | $4.99B | -1.3% |
| Operating income | $2.47B | $2.28B | $1.85B | $2.90B | +8.3% |
| Net interest income | -$142.50M | -$182.70M | $29.60M | -$157.30M | +22.0% |
| Pre-tax income | $1.56B | $1.91B | $1.30B | $3.59B | -18.3% |
| Tax provision | $263.60M | $273.80M | $135.30M | $632.80M | -3.7% |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | -20.8% |
| Net income to common | $1.29B | $1.63B | $1.16B | $3.05B | -20.8% |
| Basic EPS | 8.83 | 11.21 | 8.02 | 20.96 | -21.2% |
| Diluted EPS | 8.79 | 11.18 | 7.97 | 20.87 | -21.4% |
| EBIT | $1.82B | $2.16B | $1.54B | $3.84B | -15.4% |
| EBITDA | $2.60B | $2.83B | $2.04B | $4.36B | -8.0% |
| Basic shares | 146.50M | 145.60M | 144.70M | 145.30M | +0.6% |
| Diluted shares | 147.10M | 145.90M | 145.60M | 146.00M | +0.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.01B | $2.38B | $1.05B | $3.42B | — | +26.7% |
| Cash & short-term investments | $3.82B | $2.38B | $1.05B | $4.89B | — | +60.7% |
| Accounts receivable | $1.87B | $1.87B | $2.10B | $2.14B | — | -0.1% |
| Inventory | $2.17B | $2.46B | $2.53B | $1.34B | — | -11.9% |
| Total current assets | $8.97B | $7.46B | $6.86B | $9.79B | — | +20.3% |
| Property, plant & equipment | $3.32B | $3.54B | $3.73B | $3.70B | — | -6.1% |
| Goodwill & intangibles | $15.67B | $16.17B | $14.58B | $7.60B | — | -3.1% |
| Total assets | $29.44B | $28.05B | $26.84B | $24.55B | — | +5.0% |
| Total current liabilities | $3.35B | $5.53B | $3.43B | $3.27B | — | -39.4% |
| Current debt | — | $1.75B | $150.00M | — | $999.10M | — |
| Long-term debt | $6.29B | $4.55B | $6.79B | $6.28B | — | +38.3% |
| Total debt | $6.58B | $6.63B | $7.34B | $6.61B | — | -0.8% |
| Total liabilities | $11.18B | $11.33B | $12.05B | $11.17B | — | -1.3% |
| Retained earnings | $20.55B | $19.26B | $17.63B | $16.47B | — | +6.7% |
| Shareholder equity | $18.26B | $16.72B | $14.80B | $13.40B | — | +9.2% |
| Working capital | $5.62B | $1.93B | $3.42B | $6.52B | — | +191.7% |
| Net tangible assets | $2.59B | $545.90M | $217.20M | $5.80B | — | +373.9% |
| Shares issued | 170.60M | 169.52M | 168.70M | 167.80M | — | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.29B | $1.63B | $1.16B | $2.96B | — | -20.8% |
| Depreciation & amortisation | $779.90M | $673.20M | $494.80M | $518.40M | — | +15.8% |
| Stock-based compensation | $290.80M | $291.20M | $264.20M | $254.10M | — | -0.1% |
| Change in working capital | -$1.06B | -$155.20M | -$648.70M | -$890.30M | — | -581.4% |
| Operating cash flow | $2.20B | $2.88B | $1.55B | $1.38B | — | -23.3% |
| Capital expenditure | -$235.40M | -$359.80M | -$311.40M | -$243.20M | — | +34.6% |
| Investing cash flow | -$1.37B | -$799.20M | -$4.10B | $1.58B | — | -71.6% |
| Share buybacks | — | $0 | $0 | -$750.00M | -$1.80B | — |
| Financing cash flow | -$301.90M | -$683.50M | $149.30M | -$1.75B | — | +55.8% |
| Free cash flow | $1.97B | $2.52B | $1.24B | $1.14B | — | -21.7% |
| End cash position | $3.01B | $2.38B | $1.05B | $3.42B | — | +26.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $2.74B | $2.48B | $2.28B | $2.53B | $2.65B | +10.4% |
| Operating revenue | $2.74B | $2.48B | $2.28B | $2.53B | $2.65B | +10.4% |
| Cost of revenue | $776.90M | $661.00M | $495.50M | $674.40M | $605.00M | +17.5% |
| Gross profit | $1.96B | $1.82B | $1.78B | $1.86B | $2.04B | +7.8% |
| Research & development | $529.60M | $539.00M | $509.40M | $436.10M | $399.00M | -1.7% |
| Selling, general & admin | $709.70M | $607.30M | $682.50M | $594.80M | $583.80M | +16.9% |
| Total operating expense | $1.48B | $1.36B | $1.40B | $1.25B | $1.19B | +8.8% |
| Operating income | $482.80M | $459.80M | $385.50M | $606.50M | $851.80M | +5.0% |
| Net interest income | -$57.00M | -$29.70M | -$30.30M | -$35.80M | -$40.30M | -91.9% |
| Pre-tax income | $132.40M | $377.70M | -$56.00M | $557.30M | $744.00M | -64.9% |
| Tax provision | $34.90M | $58.20M | -$7.10M | $90.80M | $109.20M | -40.0% |
| Net income | $97.50M | $319.50M | -$48.90M | $466.50M | $634.80M | -69.5% |
| Net income to common | $97.50M | $319.50M | -$48.90M | $466.50M | $634.80M | -69.5% |
| Basic EPS | 0.66 | 2.17 | -0.33 | 3.18 | 4.33 | -69.6% |
| Diluted EPS | 0.66 | 2.15 | -0.33 | 3.17 | 4.33 | -69.3% |
| EBIT | $214.70M | $445.30M | $11.50M | $624.70M | $816.60M | -51.8% |
| EBITDA | $450.80M | $649.70M | $211.70M | $826.90M | $1.01B | -30.6% |
| Basic shares | 147.70M | 147.20M | 146.70M | 146.60M | 146.50M | +0.3% |
| Diluted shares | 148.70M | 148.40M | 146.70M | 147.10M | 146.70M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.28B | $3.38B | $3.01B | $3.86B | $2.76B | — | -62.0% |
| Cash & short-term investments | $1.28B | $4.28B | $3.82B | $3.96B | $2.76B | — | -70.0% |
| Accounts receivable | $2.40B | $1.79B | $1.87B | $1.85B | $2.08B | — | +34.0% |
| Inventory | $2.38B | $1.95B | $2.17B | $2.21B | $2.27B | — | +22.3% |
| Total current assets | $7.31B | $9.19B | $8.97B | $8.94B | $7.97B | — | -20.5% |
| Property, plant & equipment | $3.24B | $3.27B | $3.32B | $3.41B | $3.43B | — | -0.9% |
| Goodwill & intangibles | $20.51B | $15.54B | $15.67B | $15.82B | $15.96B | — | +31.9% |
| Total assets | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | — | +8.8% |
| Total current liabilities | $3.92B | $3.00B | $3.35B | $3.29B | $3.18B | — | +30.6% |
| Current debt | $800.00M | — | — | — | — | $1.75B | — |
| Long-term debt | $7.29B | $6.29B | $6.29B | $6.29B | $6.28B | — | +15.9% |
| Total debt | $8.36B | $6.56B | $6.58B | $6.59B | $6.59B | — | +27.3% |
| Total liabilities | $13.24B | $10.83B | $11.18B | $11.00B | $10.70B | — | +22.2% |
| Retained earnings | $20.97B | $20.87B | $20.55B | $20.60B | $20.14B | — | +0.5% |
| Shareholder equity | $18.85B | $18.65B | $18.26B | $18.21B | $17.63B | — | +1.1% |
| Working capital | $3.39B | $6.19B | $5.62B | $5.65B | $4.78B | — | -45.3% |
| Net tangible assets | -$1.66B | $3.11B | $2.59B | $2.38B | $1.67B | — | -153.4% |
| Shares issued | 147.70M | 171.40M | 170.60M | 170.50M | 170.40M | — | -13.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $97.50M | $319.50M | -$48.90M | $466.50M | $634.80M | -69.5% |
| Depreciation & amortisation | $236.10M | $204.40M | $200.20M | $202.20M | $194.30M | +15.5% |
| Stock-based compensation | $77.40M | $84.00M | $59.60M | $75.30M | $74.90M | -7.9% |
| Change in working capital | -$238.10M | -$127.90M | -$108.70M | $174.20M | -$789.60M | -86.2% |
| Operating cash flow | $448.90M | $645.50M | $511.90M | $1.27B | $160.90M | -30.5% |
| Capital expenditure | -$140.90M | -$86.20M | -$110.20M | -$51.50M | -$26.60M | -63.5% |
| Investing cash flow | -$3.84B | -$209.50M | -$1.23B | -$35.10M | -$57.00M | -1,732.6% |
| Financing cash flow | $1.30B | -$43.80M | -$137.00M | -$130.20M | -$11.70M | +3,058.9% |
| Free cash flow | $308.00M | $559.30M | $401.70M | $1.22B | $134.30M | -44.9% |
| End cash position | $1.28B | $3.38B | $3.01B | $3.86B | $2.76B | -62.0% |
Options analytics
Put / call volume
3.70
Put-heavy session
Put / call open interest
0.83
Positioning, not flow
Max pain
220.00
-1.3% from spot
ATM implied vol
57.2%
Nearest strike to spot
Skew (10% OTM)
+11.3%
Puts bid over calls
Call volume
50
Contracts, this expiry
Put volume
185
Contracts, this expiry
Heaviest call OI
240.00
768 contracts
Heaviest put OI
200.00
623 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 2.03 | 3.60 | +77.4% |
| Mar 2026 | 2.95 | 3.57 | +20.9% |
| Dec 2025 | 1.62 | 1.99 | +23.2% |
| Sep 2025 | 3.88 | 4.81 | +23.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.04 | 26 | $2.64B | +4.0% |
| Next quarter | 3.27 | 26 | $2.60B | +14.0% |
| Current year | 12.54 | 33 | $10.45B | +5.6% |
| Next year | 16.54 | 33 | $10.66B | +2.0% |
Analyst targets & ownership
Mean target$238.18
High target$300.00
Low target$175.00
Implied upside7.05%
Analyst count31
ConsensusBUY
Strong buy / Buy3 / 19
Hold12
Sell / Strong sell1 / 0
Held by insiders0.19%
Held by institutions99.53%
Institutions holding1.49K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
225.23
-1.21% from price
SMA 20
221.21
+0.76% from price
SMA 50
216.18
+3.10% from price
SMA 100
207.76
+7.09% from price
SMA 200
195.71
+13.89% from price
EMA 12
223.16
-0.29% from price
EMA 26
220.86
+0.74% from price
EMA 50
216.60
+2.72% from price
RSI (14)
53.4
Neutral
MACD (12,26,9)
2.30
Hist -0.47
ATR (14)
5.54
2.49% of price
Realised vol 30D
22.9%
Annualised
Bollinger upper
231.39
20, 2σ
Bollinger lower
211.03
20, 2σ
50 / 200 cross
Golden
216.18 vs 195.71
Trend bias
Above 200
+13.89%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.31
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
22.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-14.3%
Peak to trough
Max drawdown 5Y
-64.4%
Peak to trough
ATR 14
5.54
2.49% of price
Beta (reported)
0.09
5Y monthly, from filing
Short interest
Shares short
5.82M
Prior 5.19M
Change vs prior
+12.1%
Shorts adding
% of float
4.39%
Normal
% of shares out
3.94%
Against total outstanding
Days to cover
8.1
Crowded exit
Float
147.22M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 26 | HSBC | MAINTAINED | Reduce | Reduce |
| Sep 3, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 25, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 13, 26 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Aug 4, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Aug 3, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Jul 30, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 30, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 30, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Jul 30, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 30, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 30, 26 | TD Cowen | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split3:1
Split dateJan 18, 2001
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-07-01
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-14
Tender Offer/Acquisition Reports
SC TO-T/A · 2026-05-12
Tender Offer/Acquisition Reports
SC TO-T/A · 2026-05-06
Periodic Financial Reports
10-Q · 2026-04-29
Annual Report to Shareholders
ARS · 2026-04-28
Headlines
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
Proactive · 9h ago
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Zacks · 11h ago
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
GlobeNewswire · 4d ago
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
Zacks · 5d ago
1 Profitable Stock Worth Investigating and 2 We Ignore
StockStory · 6d ago
HLS Therapeutics Announces Board of Directors Changes
CNW Group · 6d ago
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Stocktwits · 8d ago
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
Zacks · 9d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.